Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Zebra 365 who wrote (4101)	5/12/1998 6:48:00 PM
From: Peter V	Read Replies (1) \| Respond to of 7041

Supposedly, ICOS' drug will be better than Viagra: "ICOS doesn't have a cure for cancer. But it does have what has proven to be the next best thing in today's market: another impotence drug. Analysts are already talking about the company's IC351 compound as the next Viagra, only without Viagra's odd side effects. ICOS' product, however, is still in Phase II clinical trials and has at least a year of testing before it is reviewed by the Food and Drug Administration. The drug works similarly to Viagra, except it is more targeted in increasing blood flow to the genitals." In any event, Vasomax will not be alone in trying to get a ED drug approved, which should further diminish the value of ZONA.